Results 101 to 110 of about 281,748 (215)

Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera [PDF]

open access: bronze, 2017
Shreekant Parasuraman   +3 more
openalex   +1 more source

Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis

open access: yesCancer Medicine, 2018
Interferon‐α2 reduces elevated blood cell counts and splenomegaly in patients with myeloproliferative neoplasms (MPN) and may restore polyclonal hematopoiesis.
S. U. Mikkelsen   +16 more
semanticscholar   +1 more source

Expert Perspective: Hematologic Malignancies and Vasculitis

open access: yes
Arthritis &Rheumatology, Volume 77, Issue 10, Page 1305-1316, October 2025.
Michelle L. Robinette, Hetty E. Carraway
wiley   +1 more source

Novel European Asiatic Clinical, Laboratory, Molecular and Pathobiological (2015-2020 CLMP) criteria for JAK2V617F trilinear polycythemia vera (PV), JAK2exon12 PV and JAK2V617F, CALR and MPL515 thrombocythemias: From Dameshek to Constantinescu-Vainchenker, Kralovics and Michiels [PDF]

open access: hybrid, 2020
Michiels Jan Jacques   +12 more
openalex   +1 more source

Chronic myelomonocytic leukemia as a transformation from polycythemia vera

open access: yesLeukemia Research Reports, 2019
The hallmark of Polycythemia vera (PV) is the presence of JAK2V617F mutation and increased RBC mass. Chronic myelomonocytic leukemia (CMML) is defined as persistent blood absolute monocyte count (AMC) >/= 1 × 109/L for at least 3 months with myeloid cell
Mirela Andrei   +3 more
doaj   +1 more source

Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival

open access: yesLeukemia, 2021
G. Abu-Zeinah   +9 more
semanticscholar   +1 more source

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project

open access: yesHaematologica, 2018
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPN)[1][1] that can progress to blast phase[2][2] and to post-PV (PPV) myelofibrosis (MF) and post-ET (PET) MF,[3][3] from now on referred to as secondary ...
B. Mora   +27 more
semanticscholar   +1 more source

A rare case of extramedullary hematopoiesis: when the pericardium produces blood cells

open access: yesThe Egyptian Heart Journal
Background Cardiac tamponade is an extreme cardiological emergency, fatal in the absence of rapid intervention. This case report highlights a noteworthy and rare correlation between post-polycythemia vera myelofibrosis and extramedullary hematopoiesis ...
SALAH-EDDINE HAYAR   +9 more
doaj   +1 more source

Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation

open access: yesHaematologica, 2014
The clinical course of polycythemia vera and essential thrombocythemia is potentially associated with long-term severe complications, such as evolution to myelofibrosis or acute myeloid leukemia. Allogeneic stem cell transplantation is currently the only
Federico Lussana   +17 more
doaj   +1 more source

Metachronous Polycythemia Vera and Multiple Myeloma in an Ethiopian patient [PDF]

open access: green, 2022
Zablon Mesfin Anbessie   +1 more
openalex   +1 more source

Home - About - Disclaimer - Privacy